Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
The overview and definition of vulvar cancer provides a clear picture of this rare yet significant disease affecting the external female genitalia. This page is designed for international patients, caregivers, and health‑conscious readers who seek reliable information about vulvar cancer, its causes, symptoms, diagnostic pathways, and treatment options. According to the World Health Organization, vulvar cancer accounts for about 5% of all gynecologic cancers, highlighting the importance of early recognition and specialized care.
In this comprehensive guide, you will learn about the anatomy of the vulva, the different histological types of cancer that can arise, and the risk factors that increase susceptibility. We also detail modern diagnostic techniques, staging systems, and the multidisciplinary treatment approaches offered at Liv Hospital, a JCI‑accredited center known for its international patient services.
Whether you are exploring symptoms you have noticed, preparing for an upcoming consultation, or simply expanding your medical knowledge, this overview and definition equips you with the essential facts to make informed decisions and engage confidently with your care team.
The vulva comprises the labia majora, labia minora, clitoral glans, vestibular glands, and the surrounding skin. Cancer can develop in any of these structures, most commonly in the labia majora and minora. The two main histological categories are:
Below is a simple comparison of the primary types:
Understanding the specific type is crucial because it guides therapeutic decisions and influences prognosis. While SCC dominates, each subtype demands a tailored approach that considers tumor biology and patient factors.
Vulvar cancer does not arise spontaneously; several modifiable and non‑modifiable risk factors contribute to its development. The most prominent cause is persistent infection with high‑risk human papillomavirus (HPV) strains, especially HPV‑16. Other important contributors include:
Genetic predispositions, such as mutations in the TP53 gene, may also increase susceptibility, though these are rarer. Reducing modifiable risks—cessation of smoking, HPV vaccination, and vigilant management of chronic dermatoses—can lower the likelihood of malignant transformation.
Clinicians at Liv Hospital conduct thorough risk assessments, incorporating lifestyle, medical history, and genetic factors to personalize surveillance strategies for high‑risk individuals.
Early vulvar cancer often presents subtly, making awareness of warning signs essential. Common symptoms include:
Because these symptoms can mimic benign conditions, regular gynecologic examinations are vital, especially for women with known risk factors. During a pelvic exam, clinicians inspect the vulva for discoloration, texture changes, and any abnormal growths. Biopsy of suspicious lesions is the definitive step to confirm malignancy.
Early detection dramatically improves outcomes. A stage I tumor confined to the vulva has a five‑year survival rate exceeding 80%, whereas advanced disease carries a markedly lower prognosis. Liv Hospital’s multidisciplinary team emphasizes prompt evaluation and employs advanced imaging, such as high‑resolution MRI, to delineate lesion extent at the earliest stage.
Accurate diagnosis relies on a combination of histopathology, imaging, and clinical assessment. The standard diagnostic pathway includes:
Staging follows the FIGO (International Federation of Gynecology and Obstetrics) system, which categorizes disease from stage I (confined to the vulva) to stage IV (distant metastasis). The table below summarizes the main stages:
Precise staging informs the multidisciplinary treatment plan, balancing curative intent with preservation of function and quality of life. Liv Hospital’s cancer board reviews each case, integrating pathology, radiology, and surgical expertise.
Management of vulvar cancer is highly individualized, reflecting tumor stage, histology, patient health, and personal preferences. Core treatment modalities include:
Below is a concise comparison of primary treatment strategies:
Liv Hospital’s integrated approach ensures that surgeons, medical oncologists, radiation oncologists, pathologists, and supportive care specialists collaborate from diagnosis through survivorship. Advanced technologies such as robotic‑assisted surgery and image‑guided radiotherapy enhance precision while minimizing morbidity.
After completing primary treatment, structured follow‑up is essential to detect recurrence early and to address long‑term side effects. Recommended surveillance includes:
Patients may experience complications such as chronic pain, altered body image, or urinary dysfunction. Liv Hospital provides dedicated rehabilitation services, counseling, and nutritional guidance to optimize quality of life. Participation in survivorship programs also offers peer support and educational resources.
Long‑term monitoring aligns with international guidelines, ensuring that any new lesions are addressed promptly and that patients receive comprehensive care throughout their survivorship journey.
Liv Hospital delivers world‑class vulvar cancer care within a JCI‑accredited environment, combining cutting‑edge technology with a 360‑degree international patient service. Our multidisciplinary team coordinates every step—from initial consultation and diagnostic work‑up to personalized treatment and post‑treatment support—while assisting with travel, accommodation, and language needs. International patients trust Liv Hospital for its expertise, compassionate approach, and seamless coordination of complex oncologic care.
Take the first step toward expert vulvar cancer care. Contact Liv Hospital today to schedule a confidential consultation and learn how our specialized team can guide you through every phase of treatment and recovery.
Send us all your questions or requests, and our expert team will assist you.
Vulvar cancer often begins with subtle changes that can be mistaken for benign conditions. Patients may notice persistent itching or burning of the vulvar skin that does not improve with standard treatments. Visible lesions, such as non‑healing ulcers or nodules, are a red flag, especially when accompanied by bleeding or discharge. Pain during sexual activity or while urinating suggests deeper involvement. A palpable mass in the vulvar region indicates tumor growth. Early recognition of these signs and prompt gynecologic examination are crucial because stage I disease has a five‑year survival rate above 80%, whereas advanced stages have poorer outcomes.
The diagnostic pathway begins with an excisional or punch biopsy, providing tissue for histopathological confirmation. Imaging plays a pivotal role: high‑resolution MRI evaluates local tissue invasion, while CT and PET‑CT assess regional lymph nodes and distant metastasis. Laboratory assessments, such as HPV typing and sentinel lymph‑node mapping, further guide management. Staging uses the FIGO classification: Stage I tumors are confined to the vulva and ≤2 cm, Stage II indicates larger or deeper lesions still limited to the vulva, Stage III involves regional inguinal/femoral nodes, and Stage IV denotes distant spread. Accurate staging informs the multidisciplinary treatment plan, balancing curative intent with functional preservation.
Persistent infection with high‑risk HPV strains, especially HPV‑16, is the most significant modifiable cause of vulvar cancer. Chronic inflammatory dermatoses such as lichen sclerosus create a precancerous environment, increasing malignant transformation risk. Lifestyle factors like smoking impair local immunity and further elevate risk. Immunosuppressed individuals, including organ‑transplant recipients, are more susceptible. Age is a non‑modifiable factor, with most cases diagnosed after 60 years. A personal history of genital cancers or precancerous lesions also raises the likelihood. Addressing modifiable risks—vaccination, smoking cessation, and management of chronic vulvar conditions—can reduce incidence.
Early‑stage disease (Stage I–II) is primarily managed with surgery—wide local excision or radical vulvectomy combined with sentinel lymph‑node biopsy—to achieve local control. For locally advanced or node‑positive disease (Stage III–IV), radiation therapy—often with concurrent platinum‑based chemotherapy—targets residual disease and nodal basins. Systemic chemotherapy, typically cisplatin‑based, is used in conjunction with radiation for better outcomes. In recurrent or metastatic settings, especially when tumors express PD‑L1, checkpoint inhibitors such as pembrolizumab have shown durable responses. Treatment decisions are made by a multidisciplinary team to balance oncologic efficacy with preservation of function and quality of life.
Post‑treatment surveillance is structured to detect recurrence early and address long‑term sequelae. Patients undergo a thorough physical examination of the vulva and inguinal nodes every 3–4 months for the first two years, then at increasing intervals up to five years. Imaging (MRI or CT) is performed based on clinical findings or symptomatology. Supportive care addresses complications like lymphedema—through physiotherapy and compression garments—sexual dysfunction, urinary issues, and chronic pain. Liv Hospital offers multidisciplinary survivorship programs that include counseling, nutrition, and peer support, aligning with international guidelines to ensure holistic long‑term health.
BlogCancerNov 03, 2025Vaginal cancer is a rare cancer that’s hard to spot early. About 70% of vaginal cancer cases are foun...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
